PureTech Health
PTCHF · OTC · United States
Share price · PTCHF
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PTCHF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Jun 2026-8.7%
- Day beforeResults of Annual General Meeting
- 26 May 2026+12.8%
Nothing announced by PTCHF that day or the session before.
- 6 May 2026-12.0%
Nothing announced by PTCHF that day or the session before.
- 1 May 2026+13.8%
- 30 Apr 2026-4.1%
- 14 Apr 2026+12.1%
Nothing announced by PTCHF that day or the session before.
- 6 Mar 2026-5.8%
Nothing announced by PTCHF that day or the session before.
- 10 Feb 2026-8.2%
Nothing announced by PTCHF that day or the session before.
- 23 Jan 2026+6.9%
Nothing announced by PTCHF that day or the session before.
- 12 Jan 2026+3.2%
Nothing announced by PTCHF that day or the session before.
Share of unusual movement by asset
For each asset, the share of PTCHF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
GlyphAllo (allopregnanolone prodrug) (SPT-300)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 17% |
| Sessions with no dated event | — | 83% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
GlyphAllo (allopregnanolone prodrug)(SPT-300) | Phase 2 | GABA-A receptorSmall molecule | Major Depressive Disorder |
| Phase 1/2 | Galectin-9 (LGALS9)Monoclonal antibody | Acute Myeloid Leukemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $4.8M | $69M | $281M | —-$134M operating cash flow | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.